Advice

Following a full submission

alitretinoin (Toctino) is accepted for use within NHS Scotland in adults who have severe chronic hand eczema that is unresponsive to treatment with potent topical corticosteroids.

Evidence is limited to a randomised placebo-controlled study where alitretinoin was superior to placebo in terms of the primary endpoint, Physician Global Assessment of response.

It is recommended that alitretinoin is dispensed by a hospital-based pharmacy.

Download detailed advice86KB (PDF)

Download

Medicine details

Medicine name:
alitretinion (Toctino)
SMC ID:
538/09
Indication:
Severe chronic hand eczema
Pharmaceutical company
Basilea Pharmaceuticals Ltd
BNF chapter
Skin
Submission type
Full
Status
Accepted
Date advice published:
09 March 2009